{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:52:36Z","timestamp":1782913956233,"version":"3.54.5"},"reference-count":42,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tjh"],"DOI":"10.4274\/tjh.galenos.2025.2025.0278","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:17:41Z","timestamp":1760537861000},"source":"Crossref","is-referenced-by-count":0,"title":["Expression of Immune Checkpoints LAG-3, CTLA-4, TIM-3 and PD-1 in Beta Thalassemia patients Treated using HbF Augmentation Therapy and Regular Transfusions"],"prefix":"10.4274","author":[{"given":"Komal","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umaima","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Muhammad Ikram","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousaf","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masood","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulab Fatima","family":"Rani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1038\/s41598-019-40089-5","article-title":"Molecular characterization of thalassemia and hemoglobinopathy in Southeastern China","volume":"9","author":"Huang","year":"2019","unstructured":"1. Huang H, Xu L, Chen M, Lin N, Xue H, Chen L, Wang Y, He D, Zhang M, Lin Y. Molecular characterization of thalassemia and hemoglobinopathy in Southeastern China. Sci Rep. 2019;9:3493.","journal-title":"Sci Rep"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. De Sanctis V, Kattamis C, Canatan D, Soliman AT, Elsedfy H, Karimi M, Daar S, Wali Y, Yassin M, Soliman N, Sobti P, Al Jaouni S, El Kholy M, Fiscina B, Angastiniotis M. \u03b2-thalassemia distribution in the old world: an ancient disease seen from a historical standpoint. Mediterr J Hematol Infect Dis. 2017;9:e2017018.","DOI":"10.4084\/mjhid.2017.018"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41431-021-00918-6","article-title":"Cascade screening for beta-thalassemia in Pakistan: development, feasibility and acceptability of a decision support intervention for relatives","volume":"30","author":"Ahmed","year":"2022","unstructured":"3. Ahmed S, Jafri H, Rashid Y, Ehsan Y, Bashir S, Ahmed M. Cascade screening for beta-thalassemia in Pakistan: development, feasibility and acceptability of a decision support intervention for relatives. Eur J Hum Genet. 2022;30:73-80.","journal-title":"Eur J Hum Genet"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Sharif Y, Irshad S, Muazzam A, Tariq MH, Kanwal A, Rasheed S, Baxter Dalrymple M, Tariq A. Assessment of patients with \u03b2-thalassemia major, undergoing tertiary care at a regional thalassemia center in Pakistan. Pakistan J Zool. 2021;53:245-250.","DOI":"10.17582\/journal.pjz\/20190630160603"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.4323\/rjlm.2020.212","article-title":"Extramedullary hematopoiesis in beta thalassemia major-case presentation","volume":"28","author":"Diaconu","year":"2020","unstructured":"5. Diaconu A, Coculescu BI, Rizea O, Herlea V, Vultur H. Extramedullary hematopoiesis in beta thalassemia major-case presentation. Rom J Leg Med. 2020;28:212-217.","journal-title":"Rom J Leg Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jtumed.2024.01.003","article-title":"Cephalometric analysis of patients with beta thalassemia receiving fetal hemoglobin induction therapy","volume":"19","author":"Amjad","year":"2024","unstructured":"6. Amjad A, Baseer N, Yousafzai YM, Safi S, Habib SH, Habib SR. Cephalometric analysis of patients with beta thalassemia receiving fetal hemoglobin induction therapy. J Taibah Univ Med Sci. 2024;19:351-358.","journal-title":"J Taibah Univ Med Sci"},{"key":"ref6","unstructured":"7. Yavropoulou MP, Anastasilakis AD, Tzoulis P, Tournis S, Rigatou E, Kassi E, Kattamis A, Makras P. Approach to the management of \u03b2 thalassemia major associated osteoporosis-a long-standing relationship revisited. Acta Biomed. 2022;93:e2022305."},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Karunaratna A, Ranasingha JS, Mudiyanse RM. Iron overload in beta thalassemia major patients. Int J Blood Transfus Immunohematol. 2017;7:33-40.","DOI":"10.5348\/ijbti-2017-32-OA-5"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1007\/s00277-021-04605-w","article-title":"Expression of the immune checkpoint receptors CTLA-4, LAG-3, and TIM-3 in \u03b2-thalassemia major patients: correlation with alloantibody production and regulatory T cells (Tregs) phenotype","volume":"100","author":"Shokrgozar","year":"2021","unstructured":"9. Shokrgozar N, Karimi M, Golmoghaddam H, Rezaei N, Moayed V, Sharifzadeh S, Arandi N. Expression of the immune checkpoint receptors CTLA-4, LAG-3, and TIM-3 in \u03b2-thalassemia major patients: correlation with alloantibody production and regulatory T cells (Tregs) phenotype. Ann Hematol. 2021;100:2463-2469.","journal-title":"Ann Hematol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"112381","DOI":"10.1016\/j.biopha.2021.112381","article-title":"Iron chelation therapy with deferiprone improves oxidative status and red blood cell quality and reduces redox-active iron in \u03b2-thalassemia\/hemoglobin E patients","volume":"145","author":"Morales","year":"2022","unstructured":"10. Morales NP, Rodrat S, Piromkraipak P, Yamanont P, Paiboonsukwong K, Fucharoen S. Iron chelation therapy with deferiprone improves oxidative status and red blood cell quality and reduces redox-active iron in \u03b2-thalassemia\/hemoglobin E patients. Biomed Pharmacother. 2022;145:112381.","journal-title":"Biomed Pharmacother"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"344","DOI":"10.18502\/ijhoscr.v18i4.16759","article-title":"Allogeneic stem cell transplant in hematological disorders: a decade of experience","volume":"18","author":"Arif","year":"2024","unstructured":"11. Arif S, Ali N, Shaikh U, Adil S, Jehanzeb H. Allogeneic stem cell transplant in hematological disorders: a decade of experience. Int J Hematol Oncol Stem Cell Res. 2024;18:344-357.","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/stcltm\/szac007","article-title":"Hurdles to the adoption of gene therapy as a curative option for transfusion-dependent thalassemia","volume":"11","author":"Thuret","year":"2022","unstructured":"12. Thuret I, Ruggeri A, Angelucci E, Chabannon C. Hurdles to the adoption of gene therapy as a curative option for transfusion-dependent thalassemia. Stem Cells Transl Med. 2022;11:407-414.","journal-title":"Stem Cells Transl Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s12288-022-01536-y","article-title":"Safety and efficacy of thalidomide and hydroxyurea combination in beta thalassemia patients","volume":"39","author":"Garg","year":"2023","unstructured":"13. Garg A, Patel K, Shah K, Trivedi D, Raj A, Yadav R, Shah S. Safety and efficacy of thalidomide and hydroxyurea combination in beta thalassemia patients. Indian J Hematol Blood Transfus. 2023;39:85-89.","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"814302","DOI":"10.3389\/fphar.2021.814302","article-title":"Investigating the efficacy and safety of thalidomide for treating patients with \u00df-thalassemia: a meta-analysis","volume":"12","author":"Lu","year":"2022","unstructured":"14. Lu Y, Wei Z, Yang G, Lai Y, Liu R. Investigating the efficacy and safety of thalidomide for treating patients with \u00df-thalassemia: a meta-analysis. Front Pharmacol. 2022;12:814302.","journal-title":"Front Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"6162","DOI":"10.1182\/bloodadvances.2022007031","article-title":"Evaluation of the combination therapy of hydroxyurea and thalidomide in \u03b2-thalassemia","volume":"6","author":"Ansari","year":"2022","unstructured":"15. Ansari SH, Ansari I, Wasim M, Sattar A, Khawaja S, Zohaib M, Hussain Z, Adil SO, Ansari AH, Ansari UH, Farooq F, Masqati NU. Evaluation of the combination therapy of hydroxyurea and thalidomide in \u03b2-thalassemia. Blood Adv. 2022;6:6162-6168.","journal-title":"Blood Adv"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1033705","DOI":"10.3389\/fimmu.2022.1033705","article-title":"In or out of control: modulating regulatory T cell homeostasis and function with immune checkpoint pathways","volume":"13","author":"Abdeladhim","year":"2022","unstructured":"16. Abdeladhim M, Karnell JL, Rieder SA. In or out of control: modulating regulatory T cell homeostasis and function with immune checkpoint pathways. Front Immunol. 2022;13:1033705.","journal-title":"Front Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1457189","DOI":"10.3389\/fimmu.2024.1457189","article-title":"Regulatory T cells: masterminds of immune equilibrium and future therapeutic innovations","volume":"15","author":"Ge","year":"2024","unstructured":"17. Ge J, Yin X, Chen L. Regulatory T cells: masterminds of immune equilibrium and future therapeutic innovations. Front Immunol. 2024;15:1457189.","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1038\/s12276-024-01340-w","article-title":"Influencing immunity: role of extracellular vesicles in tumor immune checkpoint dynamics","volume":"56","author":"Ye","year":"2024","unstructured":"18. Ye Z, Li G, Lei J. Influencing immunity: role of extracellular vesicles in tumor immune checkpoint dynamics. Exp Mol Med. 2024;56:2365-2381.","journal-title":"Exp Mol Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","unstructured":"19. Cai L, Li Y, Tan J, Xu L, Li Y. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16:101.","journal-title":"J Hematol Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.cca.2019.11.029","article-title":"Iron overload: effects on cellular biochemistry","volume":"504","author":"Sousa","year":"2020","unstructured":"20. Sousa L, Oliveira MM, Pess\u00f4a MTC, Barbosa LA. Iron overload: effects on cellular biochemistry. Clin Chim Acta. 2020;504:180-189.","journal-title":"Clin Chim Acta"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in regulatory T cells","volume":"21","author":"Huang","year":"2004","unstructured":"21. Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI, Powell JD, Pardoll DM, Drake CG, Vignali DA. Role of LAG-3 in regulatory T cells. Immunity. 2004;21:503-513.","journal-title":"Immunity"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"7513","DOI":"10.1038\/s41467-024-51930-5","article-title":"Structural basis for mouse LAG3 interactions with the MHC class II molecule I-Ab","volume":"15","author":"Ming","year":"2024","unstructured":"22. Ming Q, Antfolk D, Price DA, Manturova A, Medina E, Singh S, Mason C, Tran TH, Smalley KSM, Leung DW, Luca VC. Structural basis for mouse LAG3 interactions with the MHC class II molecule I-Ab. Nat Commun. 2024;15:7513.","journal-title":"Nat Commun"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","unstructured":"23. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219-242.","journal-title":"Immunol Rev"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1038\/s41591-023-02593-0","article-title":"The PD-1-and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial","volume":"29","author":"Luke","year":"2023","unstructured":"24. Luke JJ, Patel MR, Blumenschein GR, Hamilton E, Chmielowski B, Ulahannan SV, Connolly RM, Santa-Maria CA, Wang J, Bahadur SW, Weickhardt A, Asch AS, Mallesara G, Clingan P, Dlugosz-Danecka M, Tomaszewska-Kiecana M, Pylypenko H, Hamad N, Kindler HL, Sumrow BJ, Kaminker P, Chen FZ, Zhang X, Shah K, Smith DH, De Costa A, Li J, Li H, Sun J, Moore PA. The PD-1-and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat Med. 2023;29:2814-2824.","journal-title":"Nat Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"5000","DOI":"10.1096\/fj.14-258194","article-title":"A role for the TIM\u20103\/GAL\u20109\/BAT3 pathway in determining the clinical phenotype of multiple sclerosis","volume":"28","author":"Saresella","year":"2014","unstructured":"25. Saresella M, Piancone F, Marventano I, La Rosa F, Tortorella P, Caputo D, Rovaris M, Clerici M. A role for the TIM\u20103\/GAL\u20109\/BAT3 pathway in determining the clinical phenotype of multiple sclerosis. FASEB J. 2014;28:5000-5009.","journal-title":"FASEB J"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1251355","DOI":"10.3389\/fonc.2023.1251355","article-title":"Similarities and divergences in the metabolism of immune cells in cancer and helminthic infections","volume":"13","author":"Esperante","year":"2023","unstructured":"26. Esperante D, Guti\u00e9rrez MIM, Issa ME, Schcolnik-Cabrera A, Mendlovic F. Similarities and divergences in the metabolism of immune cells in cancer and helminthic infections. Front Oncol. 2023;13:1251355.","journal-title":"Front Oncol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/cancers13061440","article-title":"CTLA-4 in regulatory T cells for cancer immunotherapy","volume":"13","author":"Sobhani","year":"2021","unstructured":"27. Sobhani N, Tardiel-Cyril DR, Davtyan A, Generali D, Roudi R, Li Y. CTLA-4 in regulatory T cells for cancer immunotherapy. Cancers (Basel). 2021;13:1440.","journal-title":"Cancers (Basel)"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28. Kennedy A, Robinson MA, Hinze C, Waters E, Williams C, Halliday N, Dovedi S, Sansom DM. The CTLA\u20104 immune checkpoint protein regulates PD\u2010L1: PD\u20101 interaction via transendocytosis of its ligand CD80. EMBO J. 2023;42:e111556.","DOI":"10.15252\/embj.2022111556"},{"key":"ref28","unstructured":"29. Pahlevan Kakhki M. TRIzol-based RNA extraction: a reliable method for gene expression studies. J Sci I R Iran. 2014;25:13-17."},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30. Donohue DE, Gautam A, Miller SA, Srinivasan S, Abu-Amara D, Campbell R, Marmar CR, Hammamieh R, Jett M. Gene expression profiling of whole blood: a comparative assessment of RNA-stabilizing collection methods. PLoS One. 2019;14:e0223065.","DOI":"10.1371\/journal.pone.0223065"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41392-021-00811-0","article-title":"Safety and efficacy of thalidomide in patients with transfusion-dependent \u03b2-thalassemia: a randomized clinical trial","volume":"6","author":"Chen","year":"2021","unstructured":"31. Chen JM, Zhu WJ, Liu J, Wang GZ, Chen XQ, Tan Y, Xu WW, Qu LW, Li JY, Yang HJ, Huang L, Cai N, Wang WD, Huang K, Xu JQ, Li GH, He S, Luo TY, Huang Y, Liu SH, Wu WQ, Lu QY, Zhou MG, Chen SY, Li RL, Hu ML, Huang Y, Wei JH, Li JM, Chen SJ, Zhou GB. Safety and efficacy of thalidomide in patients with transfusion-dependent \u03b2-thalassemia: a randomized clinical trial. Signal Transduct Target Ther. 2021;6:405.","journal-title":"Signal Transduct Target Ther"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32. Ju W, Din G, Huang J, Zheng M, Wang X, Liu L, Wang L, Xuan S, Xiao W, Chen A. Efficacy and safety of thalidomide in patients with \u03b2-thalassemia intermedia and major. Medicine (Baltimore). 2024;103:e40328.","DOI":"10.1097\/MD.0000000000040328"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"101138","DOI":"10.1016\/j.blre.2023.101138","article-title":"Management of transfusion-dependent \u03b2-thalassemia (TDT): expert insights and practical overview from the Middle East","volume":"63","author":"El-Beshlawy","year":"2024","unstructured":"33. El-Beshlawy A, Dewedar H, Hindawi S, Alkindi S, Tantawy AA, Yassin MA, Taher AT. Management of transfusion-dependent \u03b2-thalassemia (TDT): expert insights and practical overview from the Middle East. Blood Rev. 2024;63:101138.","journal-title":"Blood Rev"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"785153","DOI":"10.3389\/fgene.2021.785153","article-title":"Current progress and future perspectives of immune checkpoint in cancer and infectious diseases","volume":"12","author":"Cai","year":"2021","unstructured":"34. Cai X, Zhan H, Ye Y, Yang J, Zhang M, Li J, Zhuang Y. Current progress and future perspectives of immune checkpoint in cancer and infectious diseases. Front Genet. 2021;12:785153.","journal-title":"Front Genet"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3389\/fimmu.2020.00487","article-title":"The role of PD-1 in acute and chronic infection","volume":"11","author":"Jubel","year":"2020","unstructured":"35. Jubel JM, Barbati ZR, Burger C, Wirtz DC, Schildberg FA. The role of PD-1 in acute and chronic infection. Front Immunol. 2020;11:487.","journal-title":"Front Immunol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"EB","year":"2015","unstructured":"36. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/tan.13872","article-title":"The immune checkpoints cytotoxic T lymphocyte antigen\u20104 and lymphocyte activation gene\u20103 expression is up\u2010regulated in acute myeloid leukemia","volume":"96","author":"Radwan","year":"2020","unstructured":"37. Radwan SM, Elleboudy NS, Nabih NA, Kamal AM. The immune checkpoints cytotoxic T lymphocyte antigen\u20104 and lymphocyte activation gene\u20103 expression is up\u2010regulated in acute myeloid leukemia. HLA. 2020;96:3-12.","journal-title":"HLA"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"102614","DOI":"10.1016\/j.ctrv.2023.102614","article-title":"Novel targets for immune-checkpoint inhibition in cancer","volume":"120","author":"Borgeaud","year":"2023","unstructured":"38. Borgeaud M, Sandoval J, Obeid M, Banna G, Michielin O, Addeo A, Friedlaender A. Novel targets for immune-checkpoint inhibition in cancer. Cancer Treat Rev. 2023;120:102614.","journal-title":"Cancer Treat Rev"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"748787","DOI":"10.3389\/fimmu.2021.748787","article-title":"Novel roles of the Tim family in immune regulation and autoimmune diseases","volume":"12","author":"Liu","year":"2021","unstructured":"39. Liu Y, Chen H, Chen Z, Qiu J, Pang H, Zhou Z. Novel roles of the Tim family in immune regulation and autoimmune diseases. Front Immunol. 2021;12:748787.","journal-title":"Front Immunol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/bjh.18508","article-title":"A comprehensive study of immune function and immunophenotyping of white blood cells from \u03b2\u2010thalassaemia\/HbE patients on hydroxyurea supports the safety of the drug","volume":"200","author":"Siriworadetkun","year":"2023","unstructured":"40. Siriworadetkun S, Thiengtavor C, Thubthed R, Paiboonsukwong K, Fucharoen S, Pattanapanyasat K, Vadolas J, Svasti S, Chaichompoo P. A comprehensive study of immune function and immunophenotyping of white blood cells from \u03b2\u2010thalassaemia\/HbE patients on hydroxyurea supports the safety of the drug. Br J Haematol. 2023;200:367-376.","journal-title":"Br J Haematol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.ccell.2022.04.018","article-title":"Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1\/PD-L1 treatment efficacy","volume":"40","author":"Long","year":"2022","unstructured":"41. Long H, Jia Q, Wang L, Fang W, Wang Z, Jiang T, Zhou F, Jin Z, Huang J, Zhou L, Hu C, Wang X, Zhang J, Ba Y, Gong Y, Zeng X, Zeng D, Su X, Alexander PB, Wang L, Wang L, Wan YY, Wang XF, Zhang L, Li QJ, Zhu B. Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1\/PD-L1 treatment efficacy. Cancer Cell. 2022;40:674-693.","journal-title":"Cancer Cell"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"816282","DOI":"10.3389\/fimmu.2022.816282","article-title":"Iron metabolism and immune regulation","volume":"13","author":"Ni","year":"2022","unstructured":"42. Ni S, Yuan Y, Kuang Y, Li X. Iron metabolism and immune regulation. Front Immunol. 2022;13:816282.","journal-title":"Front Immunol"}],"container-title":["Turkish Journal of Hematology"],"original-title":[],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T07:54:55Z","timestamp":1771833295000},"score":1,"resource":{"primary":{"URL":"https:\/\/jag.journalagent.com\/z4\/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-55798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":42,"URL":"https:\/\/doi.org\/10.4274\/tjh.galenos.2025.2025.0278","relation":{},"ISSN":["1300-7777","1308-5263"],"issn-type":[{"value":"1300-7777","type":"print"},{"value":"1308-5263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]}}}